Citation Impact
Citing Papers
PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
2011
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
2011
Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee
2020 Standout
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
2013
Management of adverse events associated with idelalisib treatment: expert panel opinion
2015
PI3K signaling in cancer: beyond AKT
2017
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
2013
Combining immunotherapy and targeted therapies in cancer treatment
2012
Neutrophils at work
2014 Standout
Kinase inhibition in autoimmunity and inflammation
2020
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
2018
The complexity of NF-κB signaling in inflammation and cancer
2013 Standout
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
2014
The PI3K pathway in B cell metabolism
2016
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas
2012
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
2013
Targeting apoptosis in cancer therapy
2020 Standout
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
2011
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Targeting autophagy in cancer
2017 Standout
Synthetic approaches to the 2013 new drugs
2015
AKT/PKB Signaling: Navigating the Network
2017 Standout
Macrophage M1/M2 polarization
2020 Standout
The PI3K Pathway in Human Disease
2017 Standout
Idelalisib: First Global Approval
2014
Cancer-related inflammation
2008 StandoutNature
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB
2012
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies
2014
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
2017
Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway
2021 StandoutNobel
Pathways and mechanisms of venetoclax resistance
2017
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
2015
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
2015
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia
2014
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
2012
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
2012
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
2018
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
2010
The phosphatidylinositol‐3 kinase I inhibitor BKM120 induces cell death in B‐chronic lymphocytic leukemia cells in vitro
2012
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor
2012
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
2014
Ibrutinib: A First in Class Covalent Inhibitor of Bruton's Tyrosine Kinase
2014
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
2015
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence
2013
Flavonoids in Cancer and Apoptosis
2018 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
The Essential Medicinal Chemistry of Curcumin
2017 Standout
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Works of Amber Gordon being referenced
Ibrutinib treatment improves T cell number and function in CLL patients
2017
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
2011
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
2010